| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |